Skip to main content
Guttmacher Institute

Search

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Highlights

  • Roe v. Wade Overturned
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • Monthly Abortion Provision Study
  • US policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Data, Videos & Visualizations

  • Data center
  • Videos
  • Infographics
  • Public-use data sets

Peer-reviewed Journals

  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • 2024 Impact Report

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
Guttmacher Institute
Donate

Highlights

  • Roe v. Wade Overturned
  • Reproductive Health Impact Study
  • Adding It Up
  • Abortion Worldwide
  • Guttmacher-Lancet Commission
  • Monthly Abortion Provision Study
  • US policy resources
  • State policy resources
  • State legislation tracker

Reports

  • Global
  • United States

Articles

  • Global research
  • US research
  • Policy analysis
  • Guttmacher Policy Review
  • Opinion

Fact Sheets

  • Global
  • United States
  • US State Laws and Policies

Data, Videos & Visualizations

  • Data center
  • Videos
  • Infographics
  • Public-use data sets

Peer-reviewed Journals

  • International Perspectives on Sexual and Reproductive Health (1975–2020)
  • Perspectives on Sexual and Reproductive Health (1969–2020)

Global

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

US

  • Abortion
  • Contraception
  • HIV & STIs
  • Pregnancy
  • Teens

Our Work by Geography

  • Global
  • Africa
  • Asia
  • Europe
  • Latin America & the Caribbean
  • Northern America
  • Oceania

Who We Are

  • About
  • Staff
  • Board
  • Job opportunities
  • Newsletter
  • History
  • Contact
  • Conflict of Interest Policy

Media

  • Media office
  • News releases

Support Our Work

  • Make a gift today
  • Monthly Giving Circle
  • Ways to Give
  • Guttmacher Guardians
  • Guttmacher Legacy Circle
  • Financials
  • 2024 Impact Report

Awards & Scholarships

  • Darroch Award
  • Richards Scholarship
  • Bixby Fellowship
Donate
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact
Statement
June 13, 2024

Destiny Lopez, Acting Co-CEO of the Guttmacher Institute, on the US Supreme Court's Decision in FDA v. AHM

“We are relieved by this outcome, but we are not celebrating. From the start, this case was rooted in bad faith and lacking any basis in facts or science. This case never should have reached our nation’s top court in the first place and the Supreme Court made the only reasonable decision by leaving access to medication abortion using mifepristone unchanged. 

“Mifepristone is safe, effective and essential. Guttmacher data show that medication abortion accounted for nearly two-thirds of abortions in the formal US health care system in 2023. Mifepristone also plays a key role in helping many people safely self-manage their abortion.” 

“Even with this baseless challenge defeated, we must remain vigilant. The anti-abortion movement is ruthlessly pursuing its end goal of banning abortion nationwide. This attempt to restrict mifepristone was just one prong of a larger strategy that has already done so much damage: Two years after Roe was overturned, abortion is banned in 14 states and severely restricted in many more. 

“In the face of relentless attacks, policymakers at all levels need to keep pushing forward expansive and protective policies that ensure everyone can access abortion care using the method that best suits their needs.” 

Topic

United States

  • Abortion

Tags

Supreme Court (SCOTUS)

Read More

Initiative

Monthly Abortion Provision Study

Policy Analysis

Medication Abortion Accounted for 63% of All US Abortions in 2023—An Increase from 53% in 2020

Policy Analysis

Medication Abortion Within and Outside the Formal US Health Care System: What You Need to Know

Resource

Interactive Map: US Abortion Policies and Access After Roe

Initiative

Roe v. Wade Overturned: Our Latest Resources

Guttmacher Institute

Center facts. Shape policy.
Advance sexual and reproductive rights.

Donate Now
Newsletter Signup  Contact Us 
  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • Contact

Footer

  • Privacy Policy
  • Accessibility Statement
© 2025 Guttmacher Institute. The Guttmacher Institute is registered as a 501(c)(3) nonprofit organization under the tax identification number 13-2890727. Contributions are tax deductible to the fullest extent allowable.